Paul Kearney Sells 4,078 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider Paul Kearney sold 4,078 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $29,850.96. Following the completion of the sale, the insider now directly owns 176,889 shares in the company, valued at $1,294,827.48. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Sera Prognostics Stock Down 3.7 %

SERA opened at $6.97 on Thursday. Sera Prognostics, Inc. has a fifty-two week low of $1.65 and a fifty-two week high of $12.35. The firm has a market cap of $232.59 million, a price-to-earnings ratio of -7.04 and a beta of 1.04. The company’s 50-day moving average price is $7.40 and its 200 day moving average price is $7.65.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.09 million. During the same period last year, the firm earned ($0.23) EPS. Research analysts anticipate that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Investors Weigh In On Sera Prognostics

Hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new stake in shares of Sera Prognostics during the first quarter worth $18,420,000. AWM Investment Company Inc. grew its holdings in shares of Sera Prognostics by 56.0% during the 1st quarter. AWM Investment Company Inc. now owns 584,664 shares of the company’s stock worth $5,320,000 after purchasing an additional 209,762 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Sera Prognostics by 100.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock valued at $892,000 after purchasing an additional 75,441 shares during the last quarter. Ballentine Partners LLC bought a new stake in shares of Sera Prognostics during the second quarter worth $294,000. Finally, Twelve Points Wealth Management LLC bought a new position in Sera Prognostics in the second quarter valued at about $257,000. Institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.